-
-
-
-
-
-
-
Increasing unusual call option volume: ALLO CORN CNK ALMU ADMA JBL SPIR OGN REPL ORBS LWLG CANE RVMD
-
-
-
-
-
-
-
Allogene reports 58% disease clearance rate in lymphoma trial
-
-
-
-
-
-
-
UBS Starts Allogene (ALLO) at Buy
-
-
-
-
-
-
-
Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c
-
-
-
-
-
-
-
Allogene Therapeutics (ALLO) announces publication of abstracts on ALLO-316
-
-
-
-
-
-
-
Allogene Therapeutics (ALLO) Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
-
-
-
-
-
-
-
Allogene Therapeutics, Inc. (ALLO) Tops Q3 EPS by 1c
-
408,296 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

